Alina Yu. Kapitannikova

Ms. Alina Yu. Kapitannikova

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ARAlexey Rzhevskiy
Alexey Rzhevskiy
AKAlina Yu. Kapitannikova
Alina Yu. Kapitannikova
SVSteven Vasilescu
Steven Vasilescu
TKTamilla Karashaeva
Tamilla Karashaeva
Sajad Razavi BazazSajad Razavi Bazaz
Sajad Razavi Bazaz
Majid Ebrahimi WarkianiMajid Ebrahimi Warkiani
Majid Ebrahimi Warkiani
Prostate cancer (PCa) diagnosis is primarily based on prostate-specific antigen (PSA) testing and prostate tissue biopsies. However, PSA testing has relatively low specificity, while tissue biopsies are highly invasive and have relatively low sensitivity at early stages of PCa. As an alternative, we developed a technique of liquid biopsy, based on isolation of circulating tumor cells (CTCs) from seminal fluid (SF). The recovery of PCa cells from SF was demonstrated using PCa cell lines, achieving an efficiency and throughput as high as 89% (±3.8%) and 1.7 mL min−1, respectively, while 99% (±0.7%) of sperm cells were disposed of. The introduced approach was further tested in a clinical setting by collecting and processing SF samples of PCa patients. The yield of isolated CTCs measured as high as 613 cells per SF sample in comparison with that of 6 cells from SF of healthy donors, holding significant promise for PCa diagnosis. The correlation analysis of the isolated CTC numbers with the standard prognostic parameters such as Gleason score and PSA serum level showed correlation coefficient values at 0.40 and 0.73, respectively. Taken together, our results show promise in the developed liquid biopsy technique to augment the existing diagnosis and prognosis of PCa.

2 December 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
ARAlexey Rzhevskiy
Alexey Rzhevskiy
AKAlina Yu. Kapitannikova
Alina Yu. Kapitannikova
DBDenis Butnaru
Denis Butnaru
ESEvgeniy V. Shpot
Evgeniy V. Shpot
SJSimon Joosse
Simon Joosse
Majid Ebrahimi WarkianiMajid Ebrahimi Warkiani
Majid Ebrahimi Warkiani
Currently, sensitive and specific methods for the detection and prognosis of early stage PCa are lacking. To establish the diagnosis and further identify an appropriate treatment strategy, prostate specific antigen (PSA) blood test followed by tissue biopsy have to be performed. The combination of tests is justified by the lack of a highly sensitive, specific, and safe single test. Tissue biopsy is specific but invasive and may have severe side effects, and therefore is inappropriate for screening of the disease. At the same time, the PSA blood test, which is conventionally used for PCa screening, has low specificity and may be elevated in the case of noncancerous prostate tumors and inflammatory conditions, including benign prostatic hyperplasia and prostatitis. Thus, diverse techniques of liquid biopsy have been investigated to supplement or replace the existing tests of prostate cancer early diagnosis and prognostics. Here, we provide a review on the advances in diagnosis and prognostics of non-metastatic prostate cancer by means of various biomarkers extracted via liquid biopsy, including circulating tumor cells, exosomal miRNAs, and circulating DNAs.

15 April 2025 in Micromachines
Verified
Journal Article
Open access
PDF file
AVArthur Volovetskiy
Arthur Volovetskiy
VNVictoria A. Novikova
Victoria A. Novikova
ABAnastasia Boloban
Anastasia Boloban
ARAlexey Rzhevskiy
Alexey Rzhevskiy
AKAlina Yu. Kapitannikova
Alina Yu. Kapitannikova
AMAnna Valer'evna Maslennikova
Anna Valer'evna Maslennikova
Investigating the molecular and genetic characteristics of circulating tumor cells (CTCs) presents a promising approach for personalizing treatment in patients with malignant neoplasms, given the limitations of traditional biopsy and histopathology. This study aimed to isolate, characterize, and analyze CTC dynamics in the peripheral blood of 30 patients with metastatic lung cancer to develop criteria for treatment response and prognosis. We detected CTCs before the start of the treatment and monitored changes during treatment, correlating these with responses evaluated by standard imaging methods. A decrease in the CTCs in the course of the therapy was linked to a favorable tumor response, while the stable CTC counts indicated a lack of response and poor survival prognosis. The OS of patients was analyzed and compared with the initial number of CTCs in peripheral blood samples. The significant reductions in median OS were evident in patients with >3 total CTCs at baseline compared to those with ≤3 total CTCs (median survival 26 months, n = 10, vs. median survival 8 months, n = 19, respectively with HR = 2.6, 95% CI 1.07 to 6.4).